IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
Trial details
- Registry ID
- NCT03902184
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as lacutamab
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaNCT03902184 | Innate Pharma | Phase 2 | Completed | 2026-01-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |